drugset
drugset / Trial / NCT00003210

Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease

NCT00003210 ↗

Phase 2 Completed 105 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of interleukin-12 in treating patients with previously treated non-Hodgkin's lymphoma or Hodgkin's disease. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill lymphoma cells.

Timeline

Start
1998-02
Primary completion
2003-11
Completion
2003-11

Drugs

EvaluationDrugModalityDoseRoute
Subject interleukin-12 Protein / enzyme biologic — Subcutaneous

Indications

Hodgkins lymphoma MALT lymphoma Waldenstrom macroglobulinemia chronic lymphocytic leukemia/small lymphocytic lymphoma diffuse large B-cell lymphoma large-cell immunoblastic lymphoma mantle cell lymphoma mycosis fungoides and variants nodal marginal zone B-cell lymphoma splenic marginal zone lymphoma